MirZyme Therapeutics Wins Institute of Physics Business Start Up Award 2025 for Transformative Innovation in Maternal Health.

BIRMINGHAM, UK – 11 December 2025 – MirZyme Therapeutics, a UK-based,

clinical stage biotechnology company developing diagnostic and therapeutic

solutions for preeclampsia, has been named the winner of the 2025 Institute of

Physics (IOP) Business Start-Up Award. The award recognises companies applying

physics and biophysics to deliver commercially scalable technologies with significant

real-world impact.

The IOP Business Awards are the Institute’s highest industry honour, awarded to

organisations demonstrating innovation, commercial potential and measurable

societal benefit. Previous winners span global leaders in medical devices, advanced

engineering, and photonics. MirZyme’s selection highlights its physics-driven

approach to addressing one of the most urgent unmet needs in maternal health.

Innovation recognised across diagnostic and therapeutic platforms

MirZyme’s winning submission focused on two core technologies.

M-PREG®, a UKCA-marked digital diagnostic, uses routinely available maternal

blood biomarkers to provide an immediate High Risk or Low Risk prediction for

preeclampsia. The platform requires no new hardware or laboratory processes,

enabling rapid adoption across hospitals and clinics, including those in low-resource

settings.

MZe786, the company’s lead therapeutic candidate, is a hydrogen sulphide–

releasing aspirin derivative developed to restore endothelial function and address

vascular dysfunction in preeclampsia. Preclinical studies have demonstrated

reductions in sFlt-1, improved placental health, and protection of both mother and

fetus. The programme is advancing toward IND-enabling toxicology studies.

Leadership comments

Professor Asif Ahmed, Founder and Executive Chairman of MirZyme Therapeutics,

said:

“Receiving the Institute of Physics Business Start-Up Award is a powerful

endorsement of our scientific approach and our mission. Physics and biophysics sit

at the heart of MirZyme’s work to understand the vascular biology of pregnancy and

the root cause of preeclampsia. By combining a scalable digital diagnostic with a first

in class oral therapeutic, we are building the first end to end platform to predict and

prevent this devastating condition. Our mission is simple: to make preeclampsia

history. One Test. One Pill. Save Two Lives.”

Professor Stephen K Smith, Chair of MirZyme’s Scientific Advisory Board, said:

“Preeclampsia remains one of the leading causes of maternal and perinatal mortality

worldwide. As clinicians we need tools that can accurately identify which women are

truly at risk and treatments that target the underlying vascular pathology. MirZyme’s

platform directly addresses both needs. If the emerging data translate into clinical

practice, this approach has the potential to change the standard of care for millions

of pregnant women.”

Baroness Brown of Cambridge, Julia King, adviser to MirZyme’s board, said:

“MirZyme is just the kind of innovation that the Institute of Physics Business Start-Up

Award should be recognising. By applying deep insights from physics and biophysics

to a critical unmet need in maternal health, the company shows how physics can

deliver real impact in the clinic and in society. As a long-time supporter of the

MirZyme team since my time as Vice-Chancellor of Aston University, I am delighted

to see this work recognised with the 2025 Business Start-Up Award.”

Global burden underscores the need

Preeclampsia affects approximately one in twelve pregnancies worldwide and

contributes to about 1,600 maternal and fetal deaths each day. Due to limited early

diagnostic tools and the absence of targeted therapeutics, premature delivery often becomes the only clinical option. MirZyme’s integrated platform presents a first-of-its-

kind, preventative approach that could be implemented at scale in both high-income and low-resource settings.

About the Institute of Physics

The Institute of Physics is the professional body for physics in the UK and Ireland,

representing more than 23,000 members across academia, industry and education.

The organisation promotes innovation, supports evidence-based policy, advances

physics education and showcases high-impact industry achievements through the

IOP Business Awards.

About MirZyme Therapeutics

MirZyme Therapeutics Ltd is a biotechnology company developing physics-informed

diagnostic and therapeutic platforms to transform maternal health. Its portfolio

includes:

• M-PREG®, a UKCA-marked digital diagnostic for risk stratification

• MZe786, an oral therapeutic targeting vascular dysfunction

• MZe686, a next-generation therapeutic candidate

• MZe miRNAs, microRNA-based maternal vascular therapeutics

Media Contact

Dr H May Rezai

Chief Operating Officer, MirZyme Therapeutics

Email: may@mirzyme.com

Phone: +44 7447 046 763

Website: www.mirzyme.com